Magnesium Bisglycinate for Health & Longevity

Created on 11/07/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Magnesium bisglycinate is a dietary supplement of magnesium bound to the amino acid glycine, sold as a well-tolerated way to raise intake. Direct evidence for this form is modest: one trial found a small improvement in self-reported insomnia. Better-known benefits come mostly from cheaper forms. It caused no more digestive upset than placebo; dangerous build-up is a real concern with poor kidney function. Its value rests on correcting low magnesium. (Full Review)

Protocol

Sleep-trial regimen
250 mg elemental magnesium daily
As bisglycinate, 30–60 minutes before bed, for four weeks
Repletion-focused intake
320–420 mg/day total
Official adult allowance; supplemental upper limit 350 mg/day
Best time of day
Evening for sleep goals
Common practice: otherwise with meals for tolerance, always separated from interacting drugs
Time to effect
Insomnia symptoms
4 weeks
Between-group difference; both groups improved within the first two weeks
Blood pressure
About one month
Meta-analysis estimate
Tissue magnesium stores
Weeks to months
A dose has no simple half-life; serum levels are held in a narrow range

Benefits

Contraindications
  • Advanced chronic kidney disease or dialysis (eGFR below 30 mL/min/1.73 m²)
  • Existing hypermagnesemia (serum magnesium above 0.95 mmol/L)
  • Myasthenia gravis
  • Primary hyperoxaluria
Key Interactions
  • Fluoroquinolone antibiotics (ciprofloxacin)
  • Tetracycline antibiotics (doxycycline)
  • Bisphosphonates (such as alendronate)
  • Integrase inhibitors (such as dolutegravir)
  • Levothyroxine
  • Gabapentin
  • Rosuvastatin
  • Proton pump inhibitors (omeprazole) and metformin
  • Antihypertensives (such as amlodipine)
  • Vitamin D3 supplements
  • Calcium supplements
  • Neuromuscular blockers (such as rocuronium)
  • Other magnesium-containing products (magnesium laxatives)
Theoretical (inferred from mechanism)
  • Sedative-hypnotics (such as zolpidem), benzodiazepines (such as lorazepam) and alcohol
  • Potassium-sparing diuretics (such as amiloride)
  • Aminoglycosides (such as gentamicin)
  • Blood-pressure-lowering supplements (potassium)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Gastrointestinal upset and loose stools; hypermagnesemia with impaired kidney function
  • Speculative: Oxalate formation from supplemental glycine

Monitoring

Marker Target Why
Serum magnesium 0.75–0.95 mmol/L Safety check (high values stop use); expected to rise
eGFR (from serum creatinine) No established target; track change from own baseline Safety check: declining values reduce or stop use
Blood pressure (home, seated) Below 130/80 mm Hg Expected to fall; safety check on antihypertensives

Cadence: Baseline serum magnesium, eGFR and home blood pressure; serum magnesium and eGFR at 8–12 weeks, then every 6–12 months; home blood pressure weekly for the first month on antihypertensives, then monthly; Insomnia Severity Index at baseline and 4 weeks when sleep is the goal; earlier testing after a dose increase, a new interacting drug or symptoms of excess

Qualitative Assessment

  • Sleep onset and quality: time to fall asleep, night wakings and morning restedness, ideally with the Insomnia Severity Index
  • Bowel habit: stool consistency
  • Muscle cramps and twitching: frequency of night cramps or eyelid twitches
  • Headache days: monthly migraine or headache days for those with migraine
  • Mood and calm: day-to-day irritability, low mood and sense of calm